Overview

SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC)

Status:
Completed

Trial end date:
2020-06-06

Target enrollment:

Participant gender:

Summary

This study will be looking at whether CY/GVAX in combination with SGI-110 is effective (recruits CD45RO+ T cells to the tumor which may be a marker of anti-tumor activity) and safe in patients with metastatic colon or rectum cancers.

Phase:

Phase 1

Details

Lead Sponsor:

Sidney Kimmel Comprehensive Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Collaborators:

Astex Therapeutics, Ltd
Susan Cohan Colon Cancer Foundation

Treatments:

Azacitidine
Cyclophosphamide
Guadecitabine
Vaccines